Table 3.

Full sample changes in adherence, disease severity, and lung function: results from paired sample T tests

	Mean difference absolute value M(SD)	95% CI	t(df)	p-value	Cohen’s d
Adherence
Full sample
Baseline to study end	.19 (.37)	− .39, -.002	− 2.14 (16)	.048	.52*
Baseline to step 1	.02 (.20)	− .12, .08	− .47 (18)	.641	.25
Step 1 to study end	.11 (.36)	− .26, .05	− 1.44 (21)	.165	.44
Only received step 1
Baseline to study end	.27 (.14)	.095, .45	4.26 (4)	.013	1.90**
Baseline to step 1	.04 (.12)	− .16, .08	− .86 (5)	.432	.35
Step 1 to study end	.30 (.21)	.08, .11	3.73 (6)	.009	1.45**
Received step 2
Baseline to study end	.40 (.24)	− .56, -.24	− 5.63 (10)	< .001	1.70**
Baseline to step 1	.02 (.24)	− .17, .14	− .22 (11)	.826	.07
Step 1 to study end	.31 (.25)	− .45, -.16	− 4.55 (13)	< .001	1.22**
Disease severity
Baseline to study end
CASI	1.00 (2.10)	.15, 1.85	2.43 (25)	.023	.48
ACT	1.46 (4.22)	− 3.24, .32	− 1.69 (23)	.104	.35
Lung function
Baseline to study end
FVC percent predicted	2.12 (27.80)	.10.53, 14.78	.35 (20)	.730	.08
FEV1 percent predicted	6.70 (18.27)	− 3.03, 16.44	1.47 (15)	.163	.37

Significant findings bolded

Variations in degrees of freedom are due to missing data

*Medium effect size; **Large effect size